Detalhe da pesquisa
1.
Improving acute promyelocytic leukemia (APL) outcome in developing countries through networking, results of the International Consortium on APL.
Blood
; 121(11): 1935-43, 2013 Mar 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-23319575
2.
All-trans retinoic acid with daunorubicin or idarubicin for risk-adapted treatment of acute promyelocytic leukaemia: a matched-pair analysis of the PETHEMA LPA-2005 and IC-APL studies.
Ann Hematol
; 94(8): 1347-56, 2015 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-25975975
3.
Internal tandem duplication of the FLT3 gene confers poor overall survival in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based chemotherapy: an International Consortium on Acute Promyelocytic Leukemia study.
Ann Hematol
; 93(12): 2001-10, 2014 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-24981688
4.
Rapid and sensitive allele-specific (AS)-RT-PCR assay for detection of T315I mutation in chronic myeloid leukemiapatients treated with tyrosine-kinase inhibitors
Clin Exp Med
; 11(1): 55-59, Mar., 2011. ilus, graf
Artigo
em Inglês
| TXTC | ID: txt-24252
5.
Methotrexate pharmacogenetics in Uruguayan adults with hematological malignant diseases.
Eur J Pharm Sci
; 109: 480-485, 2017 Nov 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-28887233
6.
The impact of medical education and networking on the outcome of leukemia treatment in developing countries. The experience of International Consortium on Acute Promyelocytic Leukemia (IC-APL).
Hematology
; 17 Suppl 1: S36-8, 2012 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-22507775
7.
Rapid and sensitive allele-specific (AS)-RT-PCR assay for detection of T315I mutation in chronic myeloid leukemia patients treated with tyrosine-kinase inhibitors.
Clin Exp Med
; 11(1): 55-9, 2011 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-20512393
8.
Molecular monitoring of imatinib in chronic myeloid leukemia patients in complete cytogenetic remission: does achievement of a stable major molecular response at any time point identify a privileged group of patients? A multicenter experience in Argentina and Uruguay.
Clin Lymphoma Myeloma Leuk
; 11(3): 280-5, 2011 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-21658656
9.
Methotrexate pharmacogenetics in Uruguayan adults with hematological malignant diseases
Eur J Pharm Sci
; 109: 480-485, 2017. tab
Artigo
em Inglês
| URUCAN | ID: bcc-5213
10.
All-trans retinoic acid with daunorubicin or idarubicin for risk-adapted treatment of acute promyelocytic leukaemia: a matched-pair analysis of the PETHEMA LPA-2005 and IC-APL studies
Ann Hematol
; xx: [10 p.], mayo, 2015. tab
Artigo
em Inglês
| URUCAN | ID: bcc-4922
11.
Internal tandem duplication of the FLT3 gene confers poor overall survival in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based chemotherapy: an International Consortium on Acute Promyelocytic Leukemia study
Ann Hematol
; xx: xx-xx, 2014.
Artigo
em Inglês
| URUCAN | ID: bcc-4817
12.
Rapid and sensitive allele-specific (AS)-RT-PCR assay for detection of T315I mutation in chronic myeloid leukemia patients treated with tyrosine-kinase inhibitors
Clin Exp Med
; 11(1): 55-59, marzo, 2011. ilus
Artigo
em Inglês
| URUCAN | ID: bcc-4299
13.
Molecular monitoring of imatinib in chronic myeloid leukemia patients in complete cytogenetic remission: does achievement of a stable major molecular response at any time point identify a privileged group of patients? A multicenter experience in Argentina and Uruguay
Clin Lymphoma Myeloma Leuk
; 11(3): 280-285, 2011. tab
Artigo
em Inglês
| URUCAN | ID: bcc-4328
14.
Reclasificación de los linfomas, diagnosticados en un período de 12 años en el Hospital Militar, utilizando la Clasificación de OMS 2001 / Reclassification of lymphomas diagnosed in 12-yaer period at the Military Hospital, using the 2001 WHO Classification
Arch. med. interna (Montevideo)
; 27(1): 1-6, 2005. tab, graf
Artigo
em Espanhol
| URUCAN | ID: bcc-3415
15.
Tratamientos de leucemia mieloide crónica con Imatinib con cobertura financiera del Fondo Nacional de Recursos / Therapies for chronic myeloid leukemia with Imatinib fundad by the National Resources Fund
Arch. med. interna (Montevideo)
; 30(1): 17-21, 2008. tab
Artigo
em Espanhol
| URUCAN | ID: bcc-3948
16.
Tratamientos de linfomas no Hodgkin con rituximab con cobertura financiera del Fondo Nacional de Recursos / Therapy of Non Hodgkin lymphoma with rituximab fundad by the National Resources Fund
Arch. med. interna (Montevideo)
; 30(1): 8-16, 2008. tab
Artigo
em Espanhol
| URUCAN | ID: bcc-3947
17.
Quimioterapia en el carcinoma "oat cell" del pulmón
Cir. Urug
; 52(2): 167-70, mar.1982. tab, graf
Artigo
em Espanhol
| URUCAN | ID: bcc-156
18.
Tratamientos de Leucemia Mieloide Crónica con IMATINIB con cobertura financiera del Fondo Nacional de Recursos / Therapies for Chronic Myeloid Leukemia with IMATINIB funded by the Fondo Nacional de Recursos
Arch. med. interna (Montevideo)
; 30(1): 17-21, mar. 2008.
Artigo
em Espanhol
| LILACS | ID: lil-537937
19.
Tratamientos de linfomas no Hodgkin con Rituximab con cobertura financiera del Fondo Nacional de Recursos / Therapy of Non Hodgkin Lymphoma with Rituximab funded by the Fondo Nacional de Recursos
Arch. med. interna (Montevideo)
; 30(1): 8-16, mar. 2008. ilus, tab
Artigo
em Espanhol
| LILACS | ID: lil-537938
20.
Tratamientos de linfomas no Hodgkin con Rituximab con cobertura financiera del Fondo Nacional de Recursos / Therapy of Non Hodgkin Lymphoma with Rituximab funded by the Fondo Nacional de Recursos
Arch. med. interna (Montevideo)
; 30(1): 8-16, mar. 2008. ilus, tab
Artigo
em Espanhol
| BVSNACUY | ID: bnu-14613